A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus RCHOP in Previously Untreated, High-intermediate

Status	Active
Effective start/end date	9/29/21 → 8/21/25

Grants and Contracts Details